MedTrace Logo

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

NCT05467293 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 257

Last updated 2024-07-30

Study results available
· View outcomes & findings →

Summary

The objective of this study is to compare the safety and efficacy of YP-P10 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Conditions

  • Dry Eye

Interventions

DRUG

0.3% YP-P10 Ophthalmic Solution

Drug: YP-P10 Ophthalmic Solution

DRUG

1% YP-P10 Ophthalmic Solution

Drug: YP-P10 Ophthalmic Solution

DRUG

YP-P10 Placebo Ophthalmic Solution (vehicle)

Placebo YP-P10 Placebo Ophthalmic Solution (vehicle)

Sponsors & Collaborators

  • Yuyu Pharma, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-27
Primary Completion
2023-03-06
Completion
2023-03-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05467293 on ClinicalTrials.gov